Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000041730 | SCV000065426 | benign | not specified | 2012-05-15 | criteria provided, single submitter | clinical testing | His4248Arg in Exon 63 of USH2A: This variant is not expected to have clinical si gnificance because it has been identified in 1.7% (65/3738) of African American chromosomes from a broad population by the NHLBI Exome Sequencing Project (http: //evs.gs.washington.edu/EVS; dbSNP rs145830318). |
ARUP Laboratories, |
RCV000756886 | SCV000884854 | benign | not provided | 2017-12-12 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000756886 | SCV000981072 | benign | not provided | 2019-09-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000756886 | SCV001105408 | benign | not provided | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000756886 | SCV001146599 | benign | not provided | 2019-02-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002504922 | SCV002812387 | likely benign | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2021-09-27 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003450769 | SCV004181948 | likely benign | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001826589 | SCV004181949 | likely benign | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Clinical Genetics, |
RCV000041730 | SCV001919213 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000041730 | SCV001969742 | benign | not specified | no assertion criteria provided | clinical testing | ||
Natera, |
RCV001826589 | SCV002088291 | benign | Usher syndrome type 2A | 2019-12-10 | no assertion criteria provided | clinical testing |